GlassScriptPhysician profile
Juan C Gonzalez
NPI 1659370963
$4,548.77
in general payments reported to CMS, 2019-2025
32 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $448 · 2021: $719 · 2022: $626 · 2023: $639 · 2024: $654 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.61 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $999.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $834.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $721.98 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $296.14 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $257.92 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $197.54 | 2019-2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $153.54 | 2021 | |
| Abbvie INC. | $151.29 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.74 | 2021-2025 | Jardiance |
| Straumann USA LLC | $76.33 | 2021 | |
| Pfizer INC. | $71.25 | 2021-2024 | |
| Glaxosmithkline, LLC. | $65.12 | 2020-2024 | Shingrix, Arexvy |
| Allergan, INC. | $62.35 | 2019-2020 | |
| Gilead Sciences, INC. | $60.51 | 2020-2021 | |
| Antares Pharma, INC. | $52.29 | 2022-2025 | Xyosted |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $44.90 | 2019-2021 | |
| Abbott Laboratories | $38.75 | 2022-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $38.43 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.51 | 2022-2023 | |
| Genentech USA, INC. | $33.29 | 2019 | |
| Esperion Therapeutics, INC. | $31.49 | 2022-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $26.61 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.16 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $20.18 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.17 | 2025 | Unithroid |
| Currax Pharmaceuticals LLC | $17.79 | 2024 | Contrave |
| Mission Medical Distribution, LLC | $15.97 | 2025 | |
| Exact Sciences Corporation | $15.92 | 2025 | The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $14.39 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $14.31 | 2022 | |
| Sumitomo Pharma America, INC. | $14.24 | 2024 | Gemtesa |
| Vistapharm, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.